Literature DB >> 34187404

Factors associated with emergency-onset diagnosis, time to treatment and type of treatment in colorectal cancer patients in Norway.

Yngvar Nilssen1, Morten Tandberg Eriksen2,3, Marianne G Guren4, Bjørn Møller5.   

Abstract

BACKGROUND: International differences in survival among colorectal cancer (CRC) patients may partly be explained by differences in emergency presentations (EP), waiting times and access to treatment.
METHODS: CRC patients registered in 2015-2016 at the Cancer Registry of Norway were linked with the Norwegian Patient Registry and Statistics Norway. Multivariable logistic regressions analysed the odds of an EP and access to surgery, radiotherapy and systemic anticancer treatment (SACT). Multivariable quantile regression analysed time from diagnosis to treatment.
RESULTS: Of 8216 CRC patients 29.2% had an EP before diagnosis, of which 81.4% were admitted to hospital with a malignancy-related condition. Higher age, more advanced stage, more comorbidities and colon cancer were associated with increased odds of an EP (p < 0.001). One-year mortality was 87% higher among EP patients (HR=1.87, 95%CI:1.75-2.02). Being married or high income was associated with 30% reduced odds of an EP (p < 0.001). Older age was significantly associated with increased waiting time to treatment (p < 0.001). Region of residence was significantly associated with waiting time and access to treatment (p < 0.001). Male (OR = 1.30, 95%CI:1.03,1.64) or married (OR = 1.39, 95%CI:1.09,1.77) colon cancer patients had an increased odds of SACT. High income rectal cancer patients had an increased odds (OR = 1.48, 95%CI:1.03,2.13) of surgery.
CONCLUSION: Patients who were older, with advanced disease or more comorbidities were more likely to have an emergency-onset diagnosis and less likely to receive treatment. Income was not associated with waiting time or access to treatment among CRC patients, but was associated with the likelihood of surgery among rectal cancer patients.

Entities:  

Keywords:  Colorectal cancer; Emergency presentation; Treatment; Waiting time

Year:  2021        PMID: 34187404     DOI: 10.1186/s12885-021-08415-1

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  14 in total

1.  Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practice.

Authors:  Inger Kristin Larsen; Tor Åge Myklebust; Tom Børge Johannesen; Bjørn Møller; Solveig Hofvind
Journal:  Breast       Date:  2018-01-05       Impact factor: 4.380

2.  Decreasing waiting time for treatment before and during implementation of cancer patient pathways in Norway.

Authors:  Yngvar Nilssen; Odd Terje Brustugun; Morten Tandberg Eriksen; Johanne Gulbrandsen; Erik Skaaheim Haug; Bjørn Naume; Bjørn Møller
Journal:  Cancer Epidemiol       Date:  2019-05-27       Impact factor: 2.984

3.  Impact of race/ethnicity and socioeconomic status on adjuvant chemotherapy use among elderly patients with stage III colon cancer.

Authors:  Mei-Chin Hsieh; Yu-Wen Chiu; Cruz Velasco; Xiao-Cheng Wu; Mary B O'Flarity; Vivien W Chen
Journal:  J Registry Manag       Date:  2013

4.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

5.  Geographic residency status and census tract socioeconomic status as determinants of colorectal cancer outcomes.

Authors:  Robert Hines; Talar Markossian; Asal Johnson; Frank Dong; Rana Bayakly
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

6.  Regional variations in cancer survival: Impact of tumour stage, socioeconomic status, comorbidity and type of treatment in Norway.

Authors:  Katrine Damgaard Skyrud; Freddie Bray; Morten Tandberg Eriksen; Yngvar Nilssen; Bjørn Møller
Journal:  Int J Cancer       Date:  2016-01-21       Impact factor: 7.396

7.  Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.

Authors:  Melina Arnold; Mark J Rutherford; Aude Bardot; Jacques Ferlay; Therese M-L Andersson; Tor Åge Myklebust; Hanna Tervonen; Vicky Thursfield; David Ransom; Lorraine Shack; Ryan R Woods; Donna Turner; Suzanne Leonfellner; Susan Ryan; Nathalie Saint-Jacques; Prithwish De; Carol McClure; Agnihotram V Ramanakumar; Heather Stuart-Panko; Gerda Engholm; Paul M Walsh; Christopher Jackson; Sally Vernon; Eileen Morgan; Anna Gavin; David S Morrison; Dyfed W Huws; Geoff Porter; John Butler; Heather Bryant; David C Currow; Sara Hiom; D Max Parkin; Peter Sasieni; Paul C Lambert; Bjørn Møller; Isabelle Soerjomataram; Freddie Bray
Journal:  Lancet Oncol       Date:  2019-09-11       Impact factor: 41.316

8.  Utilizing national patient-register data to control for comorbidity in prognostic studies.

Authors:  Yngvar Nilssen; Trond-Eirik Strand; Robert Wiik; Inger Johanne Bakken; Xue Qin Yu; Dianne L O'Connell; Bjørn Møller
Journal:  Clin Epidemiol       Date:  2014-10-24       Impact factor: 4.790

9.  Patient and tumour characteristics associated with inclusion in Cancer patient pathways in Norway in 2015-2016.

Authors:  Yngvar Nilssen; Odd Terje Brustugun; Morten Tandberg Eriksen; Erik Skaaheim Haug; Bjørn Naume; Bjørn Møller
Journal:  BMC Cancer       Date:  2020-05-30       Impact factor: 4.430

10.  Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study.

Authors:  Sara Benitez Majano; Chiara Di Girolamo; Bernard Rachet; Camille Maringe; Marianne Grønlie Guren; Bengt Glimelius; Lene Hjerrild Iversen; Edrun Andrea Schnell; Kristina Lundqvist; Jane Christensen; Melanie Morris; Michel P Coleman; Sarah Walters
Journal:  Lancet Oncol       Date:  2018-12-10       Impact factor: 41.316

View more
  3 in total

1.  Impact of two waves of Sars-Cov2 outbreak on the number, clinical presentation, care trajectories and survival of patients newly referred for a colorectal cancer: A French multicentric cohort study from a large group of university hospitals.

Authors:  Emmanuelle Kempf; Sonia Priou; Guillaume Lamé; Christel Daniel; Ali Bellamine; Daniele Sommacale; Yazid Belkacemi; Romain Bey; Gilles Galula; Namik Taright; Xavier Tannier; Bastien Rance; Rémi Flicoteaux; François Hemery; Etienne Audureau; Gilles Chatellier; Christophe Tournigand
Journal:  Int J Cancer       Date:  2022-01-17       Impact factor: 7.316

2.  Risk factors and prognostic implications of diagnosis of cancer within 30 days after an emergency hospital admission (emergency presentation): an International Cancer Benchmarking Partnership (ICBP) population-based study.

Authors:  Sean McPhail; Ruth Swann; Shane A Johnson; Matthew E Barclay; Hazem Abd Elkader; Riaz Alvi; Andriana Barisic; Oliver Bucher; Gavin R C Clark; Nicola Creighton; Bolette Danckert; Cheryl A Denny; David W Donnelly; Jeff J Dowden; Norah Finn; Colin R Fox; Sharon Fung; Anna T Gavin; Elba Gomez Navas; Steven Habbous; Jihee Han; Dyfed W Huws; Christopher G C A Jackson; Henry Jensen; Bethany Kaposhi; S Eshwar Kumar; Alana L Little; Shuang Lu; Carol A McClure; Bjørn Møller; Grace Musto; Yngvar Nilssen; Nathalie Saint-Jacques; Sabuj Sarker; Luc Te Marvelde; Rebecca S Thomas; Robert J S Thomas; Catherine S Thomson; Ryan R Woods; Bin Zhang; Georgios Lyratzopoulos
Journal:  Lancet Oncol       Date:  2022-04-06       Impact factor: 54.433

3.  Acute healthcare utilization in end-of-life among Swedish brain tumor patients - a population based register study.

Authors:  Magnus Lindskog; Torbjörn Schultz; Peter Strang
Journal:  BMC Palliat Care       Date:  2022-07-23       Impact factor: 3.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.